We’re delighted to announce the latest edition of our xMAP® Cookbook is live and available for download! As a vetted collection of methods and protocols for developing multiplex assays on the xMAP platform of your choice, the Cookbook is a valuable resource for xMAP veterans and new users alike.
Cell counting is essential for a variety of biological applications, but precise, reproducible measurements across a wide range of cell types and concentrations can be challenging. Operator-to-operator variability in particular is a common problem for traditional cell counting techniques.
In a recent webinar, Dr. Jeffrey Borgia from Rush University Medical Center in Chicago spoke about his team’s experience developing a high-throughput serology assay for monitoring the immune response to COVID-19 vaccines using the xMAP INTELLIFLEX® System.
Despite the persistent challenges presented by the ongoing pandemic, our teams delivered critical assays and reagents, scaled production of our COVID-19 offerings, expanded our team, services, and facilities, and supported scientists and healthcare providers across the world.
For vaccine development, ELISAs simply cannot provide the throughput needed. Thankfully, xMAP bead-based multiplexing technology offers a flexible and customizable platform to support both gene and protein expression assays.
One of our newest partners is RD-Biotech, a service provider based in France. The talented RD-Biotech team helps clients with services in immunology, molecular biology, and cellular engineering.
Using the new INTELLIFLEX System’s second reporting channel, our scientists teamed up with experts at the University of Rochester to design, optimize, and validate their SARS-CoV-2 antibody assay.
This year, the Luminex team was honored to attend the annual meeting of the Association of Medical Laboratory Immunologists (AMLI) which was held in our hometown of Austin, Texas. Check out highlights from this year’s conference posters using bead-based multiplexing technology
Early detection makes a real difference in outcomes for cancer patients. But for cases of colorectal cancer, detecting tumors in the earliest stages has been virtually impossible. The team at EDP Biotech is committed to changing that by developing a simple, accurate, blood-based diagnostic test for biomarkers of colorectal cancer.
We’re excited to announce the availability of our new MagPlex® Monitoring Microspheres. Designed for assay design and development, these monitoring aids make it possible for customers to monitor reporter values and reporter channel performance well-by-well.